Biotech Archives - Page 75 of 795

1 minute read

Compass Therapeutics Presents Data Demonstrating Elimination Of MHC Class I Negative Tumors In Models At 2024 AACR Annual Meeting

April 9, 12:01 PM

Major Histocompatibility Complex Class I (MHC-I) negative tumors are refractory to immune-oncology therapies, including resistance to checkpoint blockers, due to the loss of the fundamental recognition of the tumor by

CMPX

2 minute read

Why Is Small-Cap Cancer Focused Vincerx Pharma Stock Plummeting On Tuesday?

By Vandana Singh

April 9, 10:29 AM

Preliminary Phase 1 data for VIP236 and updates on pipeline progress presented by Vincerx Pharma at AACR Annual Meeting 2024. Results on VIP236 monotherapy for metastatic tumor patients, minimal adverse events observed. VIP943 Phase 1 study shows favorable safety profile for CD123+ acute myeloid leukemia and others.

VINC

2 minute read

Why Is Penny Stock Biophytis Trading Higher On Tuesday?

By Vandana Singh

April 9, 10:06 AM

Announcing OBA clinical development program by Biophytis with BIO101 (20-hydroxyecdysone) for obesity treatment. Phase 2 study expected mid-2024, with efficacy results anticipated in 2025.

BPTS

1 minute read

FDA
News

BriaCell Highlights Data For Antibody-Drug Conjugate Resistant And Central Nervous System Metastatic Breast Cancer At AACR 2024

By Benzinga Newsdesk

April 9, 8:49 AM

PFS of 4.2 months in Phase 2 ADC resistant patients receiving Bria-IMT™ pivotal Phase 3 formulation is twice that of controls in similar studiesPFS results reinforced by larger number of prior treatments in

BCTX

2 minute read

EXCLUSIVE: PainReform’s Non-Opiate Post-Surgical Pain Relief Treatment Outperforms Rival Medicine Under Various Testing Conditions

By Vandana Singh

April 9, 8:30 AM

PainReform reveals superior IVR rates of PRF-110 vs. competitors in post-surgical pain management. Findings showcase PRF-110's extended analgesic effect potential, reducing opiate dependency.

PRFX

1 minute read

Molecular Templates Presents Interim Data From MT-6402 Phase I Study In Patients With PD-L1+ Solid Tumors At 2024 AACR Annual Meeting

By Benzinga Newsdesk

April 9, 8:27 AM

The poster highlighted the following findings from the phase I dose-escalation study of MT-6402:MT-6402 has been well tolerated with no drug-related Grade 4 or Grade 5 adverse events observed MT-6402 acts uniquely

MTEM

2 minute read

Cellectis Announces Two Poster Presentations On Novel TALEN Editing Process For Gene Correction And Gene Insertion In HSPCs At The ASGCT Annual Meeting

By Benzinga Newsdesk

April 8, 4:36 PM

Cellectis (the "Company") (NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that preliminary data exploring

CLLS

2 minute read

Elevation Oncology Presents Preclinical Proof-Of-Concept Data For HER3-ADC Program At AACR Annual Meeting 2024

By Benzinga Newsdesk

April 8, 4:35 PM

-- On-track to nominate development candidate in 2024 --BOSTON, April 8, 2024 /PRNewswire/ -- Elevation Oncology, Inc. (NASDAQ:ELEV), an innovative oncology company focused on the discovery and development of selective

ELEV

5 minute read

Century Therapeutics Presents New Preclinical Data Highlighting iPSC-Derived Cell Therapy Platform Technology At The 2024 AACR Annual Meeting

By Benzinga Newsdesk

April 8, 4:07 PM

Century Therapeutics (NASDAQ:IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology and autoimmune and inflammatory disease, today announced

IPSC

1 minute read

Cardiff Oncology Presents Novel Preclinical Data At AACR Annual Meeting 2024; Supports First-Line RAS-Mutated mCRC Clinical Study

By Benzinga Newsdesk

April 8, 4:06 PM

– In RAS-mutated mCRC, novel preclinical finding demonstrates onvansertib inhibits the tumor's ability to adapt to hypoxia resulting in a significant decrease in both tumor vascularization and

CRDF